MCRB Seres Therapeutics
- 0.769
- +0.037+5.03%
- 0.790
- +0.021+2.76%
Seres Therapeutics News
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer von Moltke Lisa
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henn Matthew R.
Seres Therapeutics | 10-Q: Q3 2024 Earnings Report
Seres Therapeutics | 8-K: SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer von Moltke Lisa
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henn Matthew R.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Young Teresa L.
Seres Therapeutics | EFFECT: Others
Seres Therapeutics | 424B3: Prospectus
Seres Therapeutics | CORRESP: CORRESP
Seres Therapeutics | UPLOAD: Others
Seres Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nestlé S.A.(14.29%),Société des Produits Nestlé S.A.(14.29%)
Seres Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner NESTLE SA
Seres Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
No Data